Thread
:
TapImmune announces results from HER2/neu interim study on breast cancer
View Single Post
01-10-2013, 10:20 PM
#
1
News
Senior Member
Join Date: Oct 2007
Posts: 18,983
TapImmune announces results from HER2/neu interim study on breast cancer
TapImmune Inc. has announced that an interim safety analysis on the first five breast cancer patients treated with HER2/neu Class II antigens at Mayo Clinic, Rochester, MN., did not show any serious adverse events.
More...
News
View Public Profile
Send a private message to News
Find More Posts by News